Nancy E. Kemeny

Nancy E. Kemeny's AcademicInfluence.com Rankings

Nancy E. Kemeny

Philosophy

#5477

World Rank

#8291

Historical Rank

Logic

#2749

World Rank

#3783

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Nancy E. Kemeny Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nancy E. Kemeny's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. (2006) (1441)
The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. (1994) (1400)
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. (2005) (1127)
Actual 10-year survival after resection of colorectal liver metastases defines cure. (2007) (1031)
2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. (2001) (886)
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. (1999) (865)
Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. (1996) (760)
Intrahepatic Cholangiocarcinoma: Rising Frequency, Improved Survival, and Determinants of Outcome After Resection (2008) (690)
Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. (1987) (635)
Symptom prevalence, characteristics and distress in a cancer population (1994) (571)
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. (2018) (492)
Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. (1996) (441)
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. (2007) (410)
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. (1996) (353)
Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). (2006) (349)
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions (2014) (306)
Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases (2003) (301)
Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. (2005) (298)
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. (2007) (279)
Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. (1999) (276)
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention (2018) (272)
Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. (1992) (266)
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. (2012) (257)
Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes--A 10-year Experience at a Single Center. (2016) (252)
Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer (1997) (246)
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. (2009) (243)
Metastatic Colorectal Cancer: From Improved Survival to Potential Cure (2010) (237)
Margin Size is an Independent Predictor of Local Tumor Progression After Ablation of Colon Cancer Liver Metastases (2013) (229)
Supportive and Negative Responses in the Partner Relationship: Their Association with Psychological Adjustment Among Individuals with Cancer (2004) (225)
Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients (2015) (221)
A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic colorectal cancer (1992) (221)
Effect of Postoperative Morbidity on Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer (2008) (217)
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer. (1994) (214)
Increased accumulation of 2-deoxy-2-[18F]Fluoro-D-glucose in liver metastases from colon carcinoma. (1982) (206)
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach. (1992) (206)
Hepatic arterial infusion after liver resection. (2005) (203)
Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. (2009) (200)
Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (2005) (199)
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. (2005) (191)
Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. (1997) (191)
Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. (2016) (190)
Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. (1984) (188)
Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. (2007) (187)
Tumor and liver drug uptake following hepatic artery and portal vein infusion. (1987) (181)
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. (2006) (179)
Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. (2009) (178)
Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. (2001) (176)
Combined Portal Vein Embolization and Neoadjuvant Chemotherapy As a Treatment Strategy for Resectable Hepatic Colorectal Metastases (2008) (175)
Colorectal hepatic metastases: adjuvant chemotherapy and survival. (2009) (173)
Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study (2007) (172)
Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy (2010) (171)
Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect (1992) (169)
BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer (2014) (167)
KRAS Mutation Correlates With Accelerated Metastatic Progression in Patients With Colorectal Liver Metastases (2010) (161)
Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. (1994) (156)
Treatment of colorectal cancer: hepatic metastasis. (1996) (155)
Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? (2015) (155)
Percutaneous Microwave versus Radiofrequency Ablation of Colorectal Liver Metastases: Ablation with Clear Margins (A0) Provides the Best Local Tumor Control. (2017) (154)
Pseudomyxoma peritonei of appendiceal origin. The memorial sloan‐kettering cancer center experience (1992) (154)
Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. (1996) (147)
1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. (1998) (145)
Prognostic factors in advanced colorectal carcinoma. Importance of lactic dehydrogenase level, performance status, and white blood cell count. (1983) (144)
RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer (2015) (142)
Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. (2005) (141)
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. (2009) (140)
Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. (2015) (140)
A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. (1991) (139)
Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. (2007) (137)
Surgical Debulking and Intraperitoneal Chemotherapy for Established Peritoneal Metastases From Colon and Appendix Cancer (2001) (131)
Preoperative 5‐fluorouracil, low‐dose leucovorin, and concurrent radiation therapy for rectal cancer (1994) (130)
Long-term hepatic arterial infusion chemotherapy. Anatomic considerations, operative technique, and treatment morbidity. (1984) (127)
KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases (2014) (126)
Quantitative analysis of antibody localization in human metastatic colon cancer: a phase I study of monoclonal antibody A33. (1990) (123)
Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. (1997) (121)
An update on hepatic arterial infusion chemotherapy for colorectal cancer. (2003) (119)
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone (2016) (117)
Actual 10‐year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? (2018) (116)
Phase I/II study of hepatic arterial therapy with floxuridine and dexamethasone in combination with intravenous irinotecan as adjuvant treatment after resection of hepatic metastases from colorectal cancer. (2003) (115)
Brain metastases from colon cancer (2004) (114)
Prognostic variables in patients with hepatic metastases from colorectal cancer. Importance of medical assessment of liver involvement (1989) (113)
Management of liver metastases from colorectal cancer. (2006) (106)
The efficacy of preoperative 5‐fluorouracil, high‐dose leucovorin, and sequential radiation therapy for unresectable rectal cancer (1993) (102)
Comparison of Adjuvant Systemic Chemotherapy With or Without Hepatic Arterial Infusional Chemotherapy After Hepatic Resection for Metastatic Colorectal Cancer (2011) (101)
Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. (2005) (101)
Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. (1990) (101)
Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update (1994) (99)
Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. (2011) (99)
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. (2002) (99)
Colorectal Cancer Liver Metastases: Biopsy of the Ablation Zone and Margins Can Be Used to Predict Oncologic Outcome. (2016) (98)
Combination clinical trials with thymidine and fluorouracil: A phase I and clinical pharmacologic evaluation (1980) (96)
CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. (2011) (96)
Arterial, portal, or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. (1999) (93)
A herpes oncolytic virus can be delivered via the vasculature to produce biologic changes in human colorectal cancer. (2009) (92)
Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. (2017) (92)
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. (2009) (91)
Presurgical chemotherapy in patients being considered for liver resection. (2007) (90)
Preoperative high‐dose leucovorin/5‐fluorouracil and radiation therapy for unresectable rectal cancer (1991) (90)
The systemic chemotherapy of hepatic metastases. (1983) (89)
Response to Neoadjuvant Chemotherapy Does Not Predict Overall Survival for Patients With Synchronous Colorectal Hepatic Metastases (2009) (88)
Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. (1992) (87)
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. (2009) (87)
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. (2019) (86)
Phase I study of anticolon cancer humanized antibody A33. (2003) (86)
Evaluation of chest computed tomography in the staging of patients with potentially resectable liver metastases from colorectal carcinoma (1999) (85)
Gemcitabine‐related radiation recall preferentially involves internal tissue and organs (2004) (84)
Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. (1995) (84)
Treatment of pulmonary colorectal metastases by radiofrequency ablation. (2013) (83)
124I-huA33 Antibody PET of Colorectal Cancer (2011) (83)
The management of resectable and unresectable liver metastases from colorectal cancer (2010) (81)
A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma (1990) (79)
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. (2003) (78)
Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. (2013) (77)
Role of adjuvant therapy after resection of colorectal cancer liver metastases. (2010) (77)
False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. (2014) (77)
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. (2004) (75)
Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. (1993) (74)
Recent advances in the treatment of advanced colorectal cancer (1993) (74)
Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. (2013) (74)
Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection (2015) (73)
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581. (2011) (72)
Antiangiogenic Therapy for Primary Liver Cancer: Correlation of Changes in Dynamic Contrast-Enhanced Magnetic Resonance Imaging with Tissue Hypoxia Markers and Clinical Response (2011) (72)
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. (2009) (71)
Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial (2019) (70)
Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients. (2018) (70)
Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes (2005) (70)
Successful treatment of a desmoid tumor with doxorubicin (1993) (70)
Role of chemotherapy in the treatment of colorectal carcinoma. (1987) (69)
The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer (2018) (68)
Severe gastroduodenal ulcerations complicating hepatic artery infusion chemotherapy for metastatic colon cancer. (1986) (68)
Hepatic-arterial chemotherapy. (2001) (68)
A phase II trial of alpha‐interferon and 5‐fluorouracil in patients with advanced carcinoid and islet cell tumors (1994) (67)
Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases (2017) (66)
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer. (1994) (65)
Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. (2007) (65)
Updated long‐term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy (2016) (64)
Treatment of unresectable primary liver cancer with intrahepatic fluorodeoxyuridine and mitomycin C through an implantable pump (1992) (63)
Ki-67 is a Prognostic Biomarker of Survival after Radiofrequency Ablation of Liver Malignancies (2012) (63)
Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement (2011) (62)
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors. (1998) (61)
SMAD4 Loss in Colorectal Cancer Patients Correlates with Recurrence, Loss of Immune Infiltrate, and Chemoresistance (2018) (61)
The role of floxuridine in metastatic liver disease (2009) (60)
Biliary Sclerosis after Hepatic Arterial Infusion Pump Chemotherapy for Patients with Colorectal Cancer Liver Metastasis: Incidence, Clinical Features, and Risk Factors (2012) (60)
Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer. (1993) (59)
Role of Hepatic Artery Infusion Chemotherapy in Treatment of Initially Unresectable Colorectal Liver Metastases: A Review. (2019) (59)
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate. (1984) (59)
Diamminedichloride platinum II and cyclophosphamide in the treatment of advanced urothelial cancer (1978) (58)
Hepatic arterial infusion pump chemotherapy in the management of colorectal liver metastases: expert consensus statement. (2013) (58)
Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients. (2016) (58)
Pathologic Response to Preoperative Chemotherapy in Colorectal Liver Metastases: Fibrosis, not Necrosis, Predicts Outcome (2012) (58)
Hepatic arterial chemotherapy in metastatic colorectal patients. (1999) (58)
Treating Primary Liver Cancer with Hepatic Arterial Infusion of Floxuridine and Dexamethasone: Does the Addition of Systemic Bevacizumab Improve Results (2011) (58)
Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for the treatment of hepatic metastases from colorectal carcinoma (1990) (57)
A pilot study of hepatic artery floxuridine combined with systemic 5‐fluorouracil and leucovorin. A potential adjuvant program after resection of colorectal hepatic metastases (1993) (57)
Overexpression of E2F-1 in Lung and Liver Metastases of Human Colon Cancer is Associated with Gene Amplification (2004) (56)
A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. (2001) (55)
5‐Fluorouracil‐induced small bowel toxicity in patients with colorectal carcinoma (1999) (55)
Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations (2017) (53)
124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET (2011) (53)
Circulating Plasma Levels of MicroRNA-21 and MicroRNA-221 Are Potential Diagnostic Markers for Primary Intrahepatic Cholangiocarcinoma (2016) (51)
Predicting Tumor Response in Patients with Colorectal Hepatic Metastases (1985) (50)
Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer (2019) (50)
Therapy for metastatic colorectal carcinoma with a combination of methyl‐CCNU, 5‐fluorouracil vincristine and streptozotocin (MOF‐strep) (1980) (50)
Comparison Between Perioperative and Postoperative Chemotherapy After Potentially Curative Hepatic Resection for Metastatic Colorectal Cancer (2013) (50)
Regional infusion for colorectal hepatic metastases. A randomized trial comparing the hepatic artery with the portal vein. (1987) (49)
Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential (2018) (48)
Prognostic significance of early recurrence: a conditional survival analysis in patients with resected colorectal liver metastasis. (2013) (48)
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease. (2002) (47)
Regional chemotherapy of colorectal cancer. (1995) (45)
Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. (2003) (45)
Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma (2021) (45)
Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance (2009) (44)
Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer (2017) (44)
Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. (1994) (44)
Management of metastatic cancer to the liver. (1989) (44)
Role of intra‐arterial hepatic chemotherapy in the treatment of colorectal cancer metastases (2010) (43)
Role of chest CT in patients with negative chest X-rays referred for hepatic colorectal metastases (2006) (43)
Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy. (2014) (43)
Alfa-2A interferon and 5-fluorouracil for advanced colorectal carcinoma: the Memorial Sloan-Kettering experience. (1992) (43)
A Phase II Trial of Streptozotocin and Adriamycin in Advanced APUD Tumors (1988) (43)
Second‐line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes (2019) (43)
Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia (2016) (42)
Uridine allows dose escalation of 5‐fluorouracil when given with N‐phosphonacetyl‐L‐Aspartate, methotrexate, and leucovorin (1993) (42)
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. (2011) (42)
Clinical and genetic determinants of ovarian metastases from colorectal cancer (2017) (41)
Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer. (1987) (41)
Hepatic arterial infusion of floxuridine and dexamethasone plus high‐dose Mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma (2005) (41)
Treatment of metastatic colon cancer: "the times they are A-changing". (2013) (39)
A Phase II study of irinotecan in patients with advanced hepatocellular carcinoma (2001) (39)
Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5‐fluorouracil (1988) (39)
Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. (2015) (39)
Conversion to Complete Resection and/or Ablation Using Hepatic Artery Infusional Chemotherapy in Patients with Unresectable Liver Metastases from Colorectal Cancer: A Decade of Experience at a Single Institution (2013) (38)
Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies (2016) (38)
Combined modality therapy of extrahepatic biliary system cancer. (1990) (38)
A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. (2001) (37)
Intrahepatic arterial infusion of chemotherapy: clinical results. (2002) (37)
Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma. (2018) (37)
Current strategies using hepatic arterial infusion chemotherapy for the treatment of colorectal cancer. (2005) (37)
Floxuridine Hepatic Arterial Infusion Associated Biliary Toxicity Is Increased by Concurrent Administration of Systemic Bevacizumab (2014) (36)
Malignant thymoma: Renal metastases responding to cis‐platinum (1981) (36)
Is hepatic infusion of chemotherapy effective treatment for liver metastases? Yes! (1992) (35)
Cholangitis complicating intraarterial chemotherapy in liver metastasis. (1985) (35)
Metastatic colorectal carcinoma: A prospective randomized trial of Methyl‐CCNU, 5‐fluorouracil (5‐FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF‐strep) (1983) (34)
Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer (1981) (34)
Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases (2017) (34)
Extrahepatic Biliary System Cancer: An Update of a Combined Modality Approach (1991) (34)
Regional Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Potential Role for Dynamic Magnetic Resonance Imaging as an Imaging Biomarker and a Survival Update from Two Prospective Clinical Trials (2014) (33)
Factors Associated With Local Tumor Control and Complications After Thermal Ablation of Colorectal Cancer Liver Metastases: A 15-year Retrospective Cohort Study. (2020) (33)
Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer (2012) (33)
Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience (2010) (33)
A randomized study of two different schedules of methyl CCNU, 5‐FU and vincristine for metastatic colorectal carcinoma (1979) (31)
Assessing the optimal duration of chemotherapy in patients with colorectal liver metastases (2008) (31)
Phase II evaluation of DON (6-diazo-5-oxo-L-norleucine) in patients with advanced colorectal carcinoma. (1982) (31)
Type la glycogenosis associated with hepatocellular carcinoma (1992) (31)
Neutropenic enterocolitis in a patient with colorectal carcinoma (1997) (30)
Review of regional therapy of liver metastases in colorectal cancer. (1992) (30)
Current approaches to metastatic colorectal cancer. (1994) (30)
Pilot clinical trial of 5-[125I]iodo-2'-deoxyuridine in the treatment of colorectal cancer metastatic to the liver. (1996) (29)
Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases. (2008) (29)
Regional treatment of hepatic metastases and hepatocellular carcinoma. (1989) (28)
Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. (1989) (28)
A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer. (2002) (28)
Advances in neoadjuvant therapy for colorectal cancer with liver metastases. (2008) (28)
Treatment of Extensive Metastatic Colorectal Cancer to the Liver with Systemic and Hepatic Arterial Infusion Chemotherapy and Two-Stage Hepatic Resection: The Role of Salvage Therapy for Recurrent Disease (2014) (28)
9‐aminocamptothecin by 72‐hour continuous intravenous infusion is Inactive in the treatment of patients with 5‐fluorouracil‐refractory colorectal carcinoma (1997) (27)
Regional chemotherapy for liver-limited metastatic colorectal cancer. (2008) (27)
Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer (2019) (27)
Chemotherapy for colorectal carcinoma: one small step forward, one step backward. (1995) (26)
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer. (1992) (26)
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer (2021) (26)
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease (2007) (25)
Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion (2017) (25)
What is the potential role of hepatic arterial infusion chemo-therapy in the current armamentorium against colorectal cancer. (2011) (25)
Molecular therapies for colorectal cancer metastatic to the liver. (2002) (23)
Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer. (1992) (23)
Is intra-arterial chemotherapy worthwhile in the treatment of patients with unresectable hepatic colorectal cancer metastases? (1996) (23)
High-grade neuroendocrine carcinoma of the colon, long-term survival in advanced disease (2011) (22)
Continuous infusion fluorouracil/leucovorin and bolus mitomycin‐C as a salvage regimen for patients with advanced colorectal cancer (1995) (21)
Treatment of Liver Metastases (2003) (21)
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial (2019) (21)
Synchronous colon and renal cancers: six cases of a clinical entity. (1989) (21)
Pilot study of vemurafenib and panitumumab combination therapy in patients with BRAF V600E mutated metastatic colorectal cancer. (2015) (20)
Pharmacokinetics and dosimetry of iodine-125-IUdR in the treatment of colorectal cancer metastatic to liver. (1996) (20)
A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors (2006) (19)
Obstructive jaundice in patients receiving hepatic artery infusional chemotherapy: etiology, treatment implications, and complications after transhepatic biliary drainage. (1997) (19)
Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver. (2010) (19)
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) (1991) (19)
Colorectal Cancer: A Clinical Guide to Therapy (2001) (19)
Localization of radioiodinated monoclonal antibody in colorectal cancer. Initial dosimetry results. (1987) (19)
Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma. (1980) (18)
Liver-directed therapy in metastatic colorectal cancer (2017) (18)
Predictive molecular markers for colorectal cancer patients with resected liver metastasis and adjuvant chemotherapy. (2007) (18)
Adjuvant therapy of colorectal cancer. (1997) (18)
Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer. (2002) (18)
Regional and systemic chemotherapy for primary hepatobiliary cancers and for colorectal cancer metastatic to the liver. (2005) (18)
Intrahepatic Cholangiocarcinoma with Lymph Node Metastasis: Treatment-Related Outcomes and the Role of Tumor Genomics in Patient Selection (2021) (17)
Efficacy of postoperative 5-FU, high-dose leucovorin, and sequential radiation therapy for clinically resectable rectal cancer. (1995) (17)
Defining the needs for adjuvant therapy of rectal and colonic cancer. (1981) (17)
Liver resection after hepatic arterial infusion (HAI) plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases (2004) (16)
In vitro detection of occult bone marrow metastases in patients with colorectal cancer hepatic metastases (1998) (16)
Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients. (2019) (16)
Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases (2017) (16)
Cisplatin for adrenal cortical carcinoma. (1983) (16)
Hepatic arterial infusional chemotherapy in the management of colorectal cancer liver metastases. (2015) (16)
Characterization and Clinical Outcomes of DNA Mismatch Repair–deficient Small Bowel Adenocarcinoma (2020) (16)
Hepatic artery infusion chemotherapy for metastatic colorectal carcinoma. (2000) (15)
Preliminary results of a randomized study of intrahepatic infusion versus systemic infusion of 5-fluoro-2'-deoxyuridine for metastatic colorectal carcinoma. (1986) (15)
Angiographic identification of extrahepatic perfusion after hepatic arterial pump placement: implications for surgical prevention. (2014) (15)
Arterial embolization for salvage of hepatic artery infusion pumps. (2006) (15)
Therapy of colorectal hepatic metastases. (1986) (15)
Robotic hepatic arterial infusion pump placement. (2017) (14)
Poly I:C immunotherapy in patients with papillomas or superficial carcinomas of the bladder. (1978) (14)
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies (2009) (14)
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. (2001) (13)
Randomized Study of Intrahepatic vs Systemic Infusion of Fluorodeoxyuridine in Patients with Liver Metastases from Colorectal Carcinoma (Preliminary Results) (1984) (13)
Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment. (2022) (13)
Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. (2022) (13)
Non-surgical treatment for liver metastases. (1999) (13)
Implementation of the Group Sequential Methodology in a Randomized Trial in Metastatic Colorectal Carcinoma (1988) (13)
Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma. (1985) (13)
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer. (1988) (13)
PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer (2015) (12)
Bronchial or Pulmonary Artery Chemoembolization for Unresectable and Unablatable Lung Metastases: A Phase I Clinical Trial. (2021) (12)
A phase I trial of intrahepatic Verapamil and doxorubicin. Regional therapy to overcome multidrug resistance (1994) (12)
Nasal septum perforation and bevacizumab (2011) (12)
Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands (2019) (11)
A prospective, randomized, double‐blinded, split‐face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab‐induced acneiform rash (2017) (11)
Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review. (1992) (11)
Type Ia glycogenosis associated with hepatocellular carcinoma. (1992) (11)
Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study). (2009) (11)
Drg 1 Expression in 131 Colorectal LiverMetastases : Correlation with ClinicalVariables and Patient Outcomes (2005) (11)
Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy (2020) (10)
Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT). Results of a Phase 2 Trial (2017) (10)
Hepatic Arterial Infusion and Systemic Chemotherapy for Breast Cancer Liver Metastases (2013) (10)
Hepatic artery infusional chemotherapy in patients with unresectable colorectal liver metastases and extrahepatic disease (2012) (10)
Colorectal cancer--an undertreated disease. (1996) (10)
Phase II trial of docetaxel (Taxotere) for untreated advanced colorectal carcinoma. (1998) (10)
Implanted Hepatic Arterial Infusion Pumps (2010) (10)
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer. (1989) (10)
Extent of hepatic resection does not correlate with toxicity following adjuvant chemotherapy (2004) (10)
Neurotoxicity of the pyrimidine synthesis inhibitor N‐phosphonoacetyl‐L‐aspartate (1982) (9)
Recurrence-free survival versus overall survival as a primary endpoint for studies of resected colorectal liver metastasis: a retrospective study and meta-analysis. (2022) (9)
Unexpected increased biliary toxicity when systemic bevacizumab is added to hepatic arterial infusion. (2010) (9)
Liver and Bile Duct Cancer (2020) (8)
Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer (2004) (8)
Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1H MRS study (2013) (8)
Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma. (1982) (8)
A case report of a patient with advanced acinar cell carcinoma of the pancreas: long-term survival with regional, systemic and targeted therapy. (2013) (8)
Is neoadjuvant (neoadj) treatment necessary prior to liver resection in patients with resectable liver metastases (mets) from colorectal carcinoma (CRC) treated with post-resection hepatic arterial infusion (HAI) plus systemic (SYS) chemotherapy (2007) (8)
Biopsy and Margins Optimize Outcomes after Thermal Ablation of Colorectal Liver Metastases (2022) (7)
Hepatic arterial therapy for the treatment of metastatic colorectal cancer. (2000) (7)
Phase II trial of 4-demethoxydaunorubicin in advanced colorectal carcinoma. (1984) (7)
A phase I trial of hepatic artery fluorodeoxyuridine combined with systemic 5-fluorouracil for the treatment of metastases from colorectal cancer (1991) (7)
Genomic stratification beyond Ras/B‐Raf in colorectal liver metastasis patients treated with hepatic arterial infusion (2019) (7)
Recurrence After Liver Resection of Colorectal Liver Metastases: Repeat Resection or Ablation Followed by Hepatic Arterial Infusion Pump Chemotherapy (2020) (7)
Phase II trial of ifosfamide and mesna in advanced colorectal cancer. (1987) (7)
Intra-arterial Chemotherapy for Liver Tumors (2007) (6)
Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials. (1992) (6)
Intrahepatic Chemotherapy for Metastatic Colorectal Cancer (2000) (6)
Phase I trial of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (DEX) in combination with systemic oxaliplatin (OXAL), fluorouracil (FU) + leucovorin (LV) after resection of hepatic metastases from colorectal cancer (2005) (6)
Young patients with synchronous colorectal liver metastases (2016) (6)
Liver-Directed and Systemic Therapies for Colorectal Cancer Liver Metastases (2019) (6)
Systemic and regional chemotherapy in advanced colorectal carcinoma (1987) (6)
Phase II evaluation of pyrazofurin in patients with advanced colorectal carcinoma. (1979) (6)
The impact of hepatic arterial infusion pump chemotherapy on hepatic recurrences and survival in patients with resected colorectal liver metastases. (2019) (6)
A bi-institutional phase II study of hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone (Dex) combined with systemic gemcitabine and oxaliplatin (GemOx) for unresectable intrahepatic cholangiocarcinoma (ICC). (2018) (6)
Quantitative imaging features of pretreatment CT predict volumetric response to chemotherapy in patients with colorectal liver metastases (2018) (6)
Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. (2019) (6)
Getting Chemotherapy Directly to the Liver: The Historical Evolution of Hepatic Artery Chemotherapy. (2020) (5)
Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases (2019) (5)
Abrupt Discontinuation of the Codman Hepatic Artery Infusion Pump: Considerations in the Era of Precision Medicine. (2019) (5)
Intra‐abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines (2000) (5)
Chemotherapy of Colorectal Cancer: A Critical Analysis of Response Criteria and Therapeutic Efficacy (1978) (5)
Second-line chemotherapy (CTx) outcomes in advanced biliary cancers (ABC): A retrospective multicenter analysis. (2016) (5)
Systemic absorption of a leucovorin mouth wash: a pharmacologic study. (1987) (5)
Metastatic Colorectal Cancer to the Liver: Involve the Surgeon Early and Often (2015) (5)
Phase II study of ganetespib, an hsp-90 inhibitor, in patients with refractory metastatic colorectal cancer. (2012) (5)
A Comparison of Yttrium-90 Microsphere Radioembolization to Hepatic Arterial Infusional Chemotherapy for Patients with Chemo-refractory Hepatic Colorectal Metastases (2017) (5)
Liver resection after hepatic arterial infusion (HAI) plus systemic oxaliplatin (Oxal) combinations in pretreated patients with extensive unresectable colorectal liver metastases. (2004) (5)
Second-line management of metastatic colorectal cancer. (2008) (5)
Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. (2015) (4)
Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity. (1990) (4)
Systemic or Regional Chemotherapy for Liver Metastases from Colorectal Cancer: Has the Wheel Stopped Spinning? (2004) (4)
Survival after resection of liver metastases from colorectal cancer with poor clinical risk factors using adjuvant systemic plus hepatic arterial therapy (2008) (4)
In defense of hepatic arterial infusion for hepatic metastases of colorectal cancer. (2010) (4)
Phase II evaluation of vindesine in patients with advanced colorectal carcinoma. (1979) (4)
The re-birth of hepatic arterial infusion for colorectal liver metastases. (2013) (4)
Regional Chemotherapy of Hepatic Metastases (1989) (4)
SMAD4 loss in colorectal cancer: Correlation with recurrence, chemoresistance, and immune infiltrate. (2017) (3)
Genomic Predictors of Recurrence Patterns After Complete Resection of Colorectal Liver Metastases and Adjuvant Hepatic Artery Infusion Chemotherapy (2022) (3)
Early liver metastases after "failure" of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy? (2020) (3)
Introduction: colorectal cancer: past accomplishments and future directions I. (1999) (3)
Addition of adjuvant hepatic artery infusion to systemic chemotherapy following resection of colorectal liver metastases is associated with reduced liver‐related mortality (2020) (3)
Right versus left: Impact of primary location on survival and cure in patients undergoing hepatic resection for metastatic colon cancer. (2017) (3)
Improving response and outcomes for patients with liver-limited metastatic colorectal cancer. (2010) (3)
Safe and Successful Yttrium-90 Resin Microsphere Radioembolization in a Heavily Pretreated Patient with Chemorefractory Colorectal Liver Metastases after Biliary Stent Placement above the Papilla (2014) (3)
Adjuvant Hepatic Artery Infusion Chemotherapy is Associated With Improved Survival Regardless of KRAS Mutation Status in Patients With Resected Colorectal Liver Metastases: A Retrospective Analysis of 674 Patients. (2020) (3)
Prospective Phase II Trial of Combination Hepatic Artery and Systemic Chemotherapy for Unresectable Colorectal Liver Metastases: Long-Term Results and Curative Potential (2016) (3)
1032 Preliminary results of pre-operative 5-FU, low dose leucovorin (LV), and concurrent radiation therapy (RT) for resectable T3 rectal cancer (1996) (3)
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions (2014) (3)
Phase I evaluation of a biochemically designed combination: PALA, thymidine, and 5-FU. (1984) (3)
Abstract No. 140: Wound Healing Complications Following Mediport Placement in Patients Treated with Bevacizumab (2009) (3)
Hepatic arterial infusion (HAI) therapy in patients with unresectable primary liver cancer: Use of dynamic contrast enhanced MRI to evaluate response (2005) (3)
Abstract No. 24: Clinical outcomes of radiofrequency ablation for colorectal cancer hepatic metastases (2008) (3)
Randomized study of intrahepatic (H) versus systemic (S) infusion of fluorodeoxyuridine (FUDR) in patients with liver metastases from colorectal carcinoma (CRC) (1987) (3)
Platinum-based combination therapy (PCT) and outcomes for patients (pts) with mixed hepatocellular carcinoma and intrahepatic cholangiocarcinoma (mHCC/ICC). (2015) (3)
Phase II trial of N-methylformamide in patients with advanced colorectal carcinoma. (1986) (3)
Predictors of a true complete response in colorectal liver metastases that disappear radiographically following chemotherapy (2007) (3)
Percutaneous liver venous deprivation: outcomes in heavily pretreated metastatic colorectal cancer patients. (2021) (2)
Relevance of CEA and LDH in relation to KRAS status in patients with unresectable colorectal liver metastases. (2016) (2)
PCN13 COST-EFFECTIVENESS OF HEPATIC ARTERY INFUSION FOR METASTATIC COLORECTAL CANCER (CALGB 9481) (2005) (2)
Phase I trial of pre-operative combined radiation therapy, 5-FU, and low dose leucovorin for unresectable rectar cancer (1992) (2)
Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases. (2013) (2)
Characterization and clinical outcomes of mismatch repair deficient (dMMR) small bowel adenocarcinoma (SBA). (2019) (2)
Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma. (1980) (2)
A phase II study of induction PD-1 blockade in subjects with locally advanced mismatch repair-deficient rectal adenocarcinoma. (2020) (2)
Improvement in long-term survival in patients with metastatic colorectal cancer (CRC) after liver resection with modern chemotherapy and hepatic arterial infusion (HAI). (2015) (2)
Genomic Stratification of Resectable Colorectal Liver Metastasis Patients and Implications for Adjuvant Therapy and Survival (2021) (2)
Response rates to hepatic arterial infusion (HAI) pump therapy in patients with metastatic colorectal cancer liver metastases (mCRC LM) after progression on all standard chemotherapies. (2014) (2)
Phase II evaluation of metoprine in advanced pancreatic adenocarcinoma. (1984) (2)
Changing Paradigms for Liver Resection of Colorectal Metastases (2012) (2)
Interventional Oncology: Pharmacologic Principles of Regional Therapy in the Treatment of Liver Metastases or Primary Liver Tumors (2008) (2)
The Role of Hepatic Arterial Infusion Chemotherapy in the Management of Patients with Hepatic Metastases from Colorectal Cancer (2007) (2)
A complication of prolonged infusional chemotherapy masquerading as a bone metastasis in a patient with colorectal carcinoma (1987) (2)
Timing of Primary Tumor Resection in Synchronous Metastatic Colon Cancer Patients Undergoing Hepatic Arterial Infusion Pump Placement (2021) (2)
Comparative genomic analysis of primary versus metastasis in colorectal carcinomas. (2011) (2)
Considerations and barriers to starting a new HAI pump program: an international survey of the HAI Consortium Research Network. (2022) (2)
Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity. (2022) (2)
Continued Survival of More Than Ten Years, Without Resection of Metastatic Disease, in Patients With Metastatic Colorectal Cancer Treated With Biomodulated Fluorouracil: Report of Two Cases (2006) (2)
A prospective analysis of germline alterations (GA) in biliary tract cancer (BTC). (2017) (2)
Hepatic artery therapies for unresectable colorectal liver metastases: Pooled survival analysis of 968 patients from TACE, yttrium-90, and HAI studies. (2017) (2)
Phase II trial of bisantrene in advanced colorectal carcinoma. (1983) (2)
Comprehensive molecular profiling and analysis of mutual exclusivity of genetic aberrations (MEGA) of intra- and extrahepatic cholangiocarcinomas (IHC and EHC) evaluation of prognostic features and potential targets for intervention. (2016) (2)
Phase II study of 2,2'-anhydro-1-beta-D-arabinofuranosyl-5-fluorocytosine in advanced colorectal carcinoma. (1978) (2)
Metastatic Liver Cancer (2009) (2)
Enhancement patterns of colorectal liver metastases on pre-sirt mapping CT arteriography correlates with FDG-PET SUVmax metabolic response (2015) (2)
Phase II trial of esorubicin in patients with advanced colorectal carcinoma. (1986) (2)
Analysis of prior malignancies in patients with cholangiocarcinoma. (2017) (2)
Liver metastases (1999) (2)
Characterization of rectal cancer in patients with Lynch syndrome. (2013) (1)
Selective Continuous Intra‐Arterial Chemotherapy for Liver Tumors (2009) (1)
Using mutational load in next generation sequencing (NGS) to identify mismatch repair (MMR) deficiency in colorectal cancer (CRC). (2015) (1)
A Randomized Phase II Trial of Adjuvant Hepatic Arterial Infusion and Systemic Therapy With or Without Panitumumab After Hepatic Resection of KRAS Wild-type Colorectal Cancer (2021) (1)
The adrenal gland: Fascinating, but still many advances to be made (2012) (1)
Variability in genomic alterations between right- and left-sided microsatellite stable (MSS) metastatic colorectal cancer and impact on survival. (2017) (1)
Extrahepatic recurrence rates in patients receiving adjuvant hepatic artery infusion and systemic chemotherapy after complete resection of colorectal liver metastases (2020) (1)
Influence of KRAS mutation on recurrence patterns in patients undergoing hepatic resection of colorectal metastases. (2013) (1)
Adjuvant Hepatic Arterial Infusion Therapy (2019) (1)
Effect of perioperative complications on recurrence and survival after resection of hepatic colorectal metastases: Analysis of data from a randomized controlled trial. (2012) (1)
Factors influencing outcome after pulmonary resection for colorectal cancer (CRC) metastases in the current era (2008) (1)
Treatment of patients with colorectal cancer: emphasis on liver metastases (2009) (1)
Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1H MRS study (2014) (1)
Percutaneous microwave ablation for colorectal cancer liver metastasis: initial results (2014) (1)
Dynamic contrast enhanced MRI (DCE-MRI) to measure antiangiogenic therapy and predict treatment response in primary liver cancer (PLC). (2010) (1)
Percutaneous Ethanol Injection (2003) (1)
Long-term outcome of unresectable metastatic colorectal cancer: does "adjuvant" chemotherapy play a role after resection? (2009) (1)
A comparative assessment of the incidence of steatohepatitis seen with modern chemotherapy agents (2005) (1)
Preliminary Results of a Randomized Study of Intrahepatic Infusion versus Systemic Infusion of FUDR for Metastatic Colorectal Carcinoma (1986) (1)
A phase III randomized double-blind study of prophylactic topical dapsone 5% versus moisturizer for cetuximab-induced papulopustular (acneiform) rash. (2015) (1)
Survival in Patients with Intrahepatic Cholangiocarcinoma and Positive Lymph Nodes: No Benefit of Resection over Hepatic Arterial Infusion Chemotherapy (2020) (1)
Pump-Based Hepatic Arterial Infusional Therapy (2019) (1)
Induction chemotherapy followed by chemoradiotherapy and total mesenteric excision for locally advanced rectal cancer with resectable metastases. (2013) (1)
Chemotherapy for colorectal cancer. (1994) (1)
Is conversion to resection possible with hepatic arterial infusion (HAI) and systemic (SYS) even in previously treated patients (pts) with unresectable colorectal liver metastases (UnCLM) (2012) (1)
Bevacizumab in the management of colorectal cancer: A review (2011) (1)
‘Tomudex’ (raltitrexed) plus 5-fluorouracil: a promising option for the treatment of patients with metastatic colorectal cancer (1999) (1)
Liver-directed conversion therapy in metastatic colon cancer. (2015) (1)
Hepatic Artery Infusion (2002) (1)
80 – Liver and Bile Duct Cancer (2014) (1)
Hepatic arterial pump perfusion. The value of macroaggregated albumin (MAA) SPECT/CT in comparison with MAA planar and SPECT imaging (2007) (1)
Hepatic arterial infusion (HAI) chemotherapy via the medtronic pump-assessing dose delivery, response rates and toxicity. (2020) (1)
CASE REPORT: Persistent CEA Elevation in a Patient with Psoriasis and a History of Metastatic Colorectal Cancer with No Evidence of Residual Tumor (2004) (1)
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: Does the addition of systemic bevacizumab improve results? (2011) (1)
Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min. (2016) (1)
Treatment decision-making preferences in older patients with metastatic colorectal cancer. (2006) (1)
Hepatic Directed Therapy (2006) (1)
A phase I clinical and pharmacokinetic study of escalating doses of fixed rate and escalating infusion duration of gemcitabine given via an intrahepatic pump for patients with hepatic metastases. (2006) (1)
In reply [8] (2007) (1)
Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients (2020) (1)
Oligometastases of Gastrointestinal Cancer Origin (2017) (1)
Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma. (1981) (1)
Transport limits cellular entry of hepatic arterially injected 5-[18F]fluoro-2'-deoxyuridine in human intrahepatic tumors. (1994) (1)
Hepatic Artery Infusion Pumps (2022) (1)
Influence of WNT and DNA damage response pathway alterations on outcomes in patients with unresectable metastatic colorectal cancer. (2019) (1)
Mathematical model of 5-[125I]iodo-2'-deoxyuridine treatment: continuous infusion regimens for hepatic metastases. (1998) (1)
Does the underlying etiology of HCC effect outcome? A single-institution analysis. (2011) (1)
Interventional Oncology: Clinical Management of Patients with Colorectal Liver Metastasis Using Hepatic Arterial Infusion (2008) (1)
Chapter 86 – Regional chemotherapy for liver tumors (2012) (1)
Treatment of liver metastases with hepatic arterial infusion (2002) (1)
Robustness of response: A new measure of response assessment: Its impact on metricies of response in colorectal cancer (2005) (1)
Intraarterial Chemotherapy for Liver Metastases. (2021) (1)
PP29 Tissue factor expression in colorectal cancer: a surrogate for KRAS and p53? (2009) (0)
Infusional 5-FU: The 24-hour weekly approach Clause-Henning Köhne (2001) (0)
A Case Report of a Patient with Advanced Acinar Cell Carcinoma of the Pancreas: Long-Term Survival with Regional, Systemic and Targeted Therapy (2013) (0)
The Precision of Hepatic Arterial Infusion Scintigraphy as a Quantitative Biomarker of Tumor Microvasculature. (2017) (0)
Phase II evaluation of metoprine in patients with advanced colorectal carcinoma. (1981) (0)
Defining the Role of Hepatic Arterial Infusion Chemotherapy in Metastatic Colorectal Cancer (2004) (0)
Association of adjuvant hepatic artery infusion chemotherapy after resection of colorectal liver metastases with improved survival in patients with both right- and left-sided primary tumors. (2018) (0)
Applying tumor genotyping and new clinical approaches to the management of colorectal cancer. (2015) (0)
Su1530 Robotic Hepatic Artery Infusion Pump Placement (2016) (0)
CT-guided radiofrequency ablation in the management of pulmonary colorectal metastases. (2011) (0)
Hepatic arterial infusion (HAI) in the treatment of breast cancer with liver metastases (BCLM) in patients (pts) who progressed after hormonal and systemic chemotherapy (CTx). (2011) (0)
SAT-05 Hepatic arterial therapy (HAI) for the treatment of colorectal liver metastases (2013) (0)
Intrahepatic Chemotherapy 2 for Metastatic Colorectal Cancer (2017) (0)
Pilot clinical trial of 5-[{sup 125}I] iodo-2{prime}-deoxyuridine in the treatment of colorectal cancer metastic to the liver (1996) (0)
Clinical prognostic factors and genomic analysis of ovary metastases (mets) from colorectal cancer (CRC). (2016) (0)
Adjuvant treatment in Dukes B2 colon cancer: No Charles Erlichman, Daniel J Sargent (2001) (0)
Influence of variant arterial anatomy and surgical technique on technical complications in hepatic arterial infusion therapy (1998) (0)
Genetic heterogeneity of intrahepatic cholangiocarcinoma: Implications for outcome. (2023) (0)
Therapy for colorectal cancer. (1991) (0)
Acknowledgement to Reviewers (2011) (0)
utcomes after Resection of Synchronous r Metachronous Hepatic and Pulmonary olorectal Metastases (2007) (0)
Percutaneous r adiofrequency ablation of colorectal cancer liver Metastases: Factors Affecting Outcomes—A 10-year Experience at (2016) (0)
Role of local liver therapy for hepatic metastases from colorectal cancer. (2009) (0)
Hepatic arterial infusion for unresectable intrahepatic cholangiocarcinoma: An update on survival from two prospective clinical trials. (2013) (0)
Update of Recommendat ions for the Use of Tumor Markers in Breast and Colorecta l Cancer : Cl in ica l Pract ice Guidel ines of the American Socie ty of Cl in ica l Oncology * (2001) (0)
Prior chemotherapy does not alter outcome of major liver resection (1998) (0)
Tumor viability and ablation margin at the end of RF ablation of colorectal liver metastases predict local progression-free survival (2015) (0)
Treatment of patients with colorectal cancer: emphasis on liver metastases. (2009) (0)
Extraordinary survivorship after colorectal liver metastasis resection to identify a distinct molecular profile associated with survival in an independent cohort of 965 patients. (2017) (0)
Hepatic artery infusion for liver metastases (2002) (0)
Colorectal Cancer: Epidemiology and Treatment (2002) (0)
Detection of IDH1 mutations in circulating free DNA in patients with cholangiocarcinoma (2016) (0)
Abstract 4380: Integrative genomics analysis of metastatic colorectal cancer (2017) (0)
Long-Term Survival with Surgery for Nodal Recurrence Following Complete Response to Therapy for De-Novo , Stage IV , Liver-Limited Colorectal Cancer (2017) (0)
Combining hepatic arterial infusion and systemic therapy: radiologic versus surgical approaches. (2012) (0)
Halt in Production of Codman Pump Leaves Questions (2018) (0)
Chapter 99 – Regional chemotherapy for liver tumors (2017) (0)
Clinical outcomes in patients age 40 or younger at diagnosis of synchronous metastatic colorectal cancer: A 20-year experience at Memorial Sloan-Kettering Cancer Center. (2011) (0)
Principles of intra-arterial infusional chemotherapy in the treatment of liver metastases from colorectal cancer (2016) (0)
1325 Regulation of Tissue factor (TF) in colorectal cancer: association with KRAS (2009) (0)
Somatic tumor profiling of DNA mismatch repair deficient (MMR-D) colorectal cancers (CRC). (2016) (0)
Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival. (2023) (0)
Poor prognosis in patients with resectable KRAS-MUT colorectal liver metastases is improved by adjuvant hepatic arterial infusion chemotherapy. (2017) (0)
4:12 PM Abstract No. 340 Review of complications following thermal ablation of colorectal cancer liver metastases (2018) (0)
Correlation between comprehensive molecular profiling and clinical outcomes in patients with colorectal liver metastases. (2016) (0)
Randomized phase II trial of adjuvant hepatic arterial infusion (HAI) + systemic FOLFIRI +/- panitumumab (Pmab) in patients with resected RAS wild type colorectal cancer hepatic metastases (CRLM). (2019) (0)
Perceived Negative Spouse Behaviors Scale (2014) (0)
Immediate post-thermal ablation biopsy of colorectal liver metastases to predict oncologic outcomes. (2020) (0)
Is PET scan conversion from positive to negative a prognostic indicator for patients receiving therapy for unresectable liver metastases from colorectal carcinoma (CRC)? (2011) (0)
Ki67 as a prognostic biomarker of 5-year oncologic outcomes following ablation of liver malignancies. (2011) (0)
Adjuvant hepatic arterial infusion chemotherapy is associated with superior survival after resection of colorectal liver metastases: A propensity score analysis of 2368 patients (2016) (0)
Radioembolization as a salvage therapy for heavily pre-treated patients with colorectal cancer liver metastases: factors affecting outcomes (2016) (0)
Conversion to complete surgical treatment using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer. (2012) (0)
Recurrence rate and pattern after resection of colorectal liver metastases with and without hepatic arterial infusion chemotherapy (2018) (0)
colorectal cancer l iver Metastases: Biopsy of the Ablation Zone and Margins Can be Used to (2016) (0)
Front & Back Matter (2017) (0)
Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases; a phase II trial (2020) (0)
Abstract No. 168: Yttrium 90 resin microspheres as a salvage treatment for colon cancer liver metastases progressing after at least two prior lines of systemic chemotherapy: preliminary results (2012) (0)
Regional Infusion Chemotherapy for Colorectal Hepatic Metastases (1986) (0)
Phase I trial of yttrium 90 resin microspheres in the treatment of colon cancer liver metastases progressing despite hepatic arterial as well as systemic chemotherapy: Preliminary results. (2012) (0)
Initial Results of Image Guided High Dose Single Fraction Radiation of Liver Metastases Treated under Conditions of Apnea under General Anesthesia (2010) (0)
Issue Information ‐ TOC (2016) (0)
Impact of KRAS on outcomes of patients with unresectable colorectal liver metastases (CRLM). (2014) (0)
Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC). (2016) (0)
Sclerosing cholangitis due to intra-arterial hepatic infusion with chemotherapy: management with non-surgical biliary drainage (1993) (0)
Adjuvant postoperative radiation therapy for resectable rectal cancer. (1991) (0)
disseminated colorectal cancer . with cytotoxic chemotherapy for concentration in patients treated Significance of a fall in serum CEA (2006) (0)
Phase I Trial of 7 V-( Phosphonacetyl )-L-aspartate , Methotrexate , and 5-Fluorouracil with Leucovorin Rescue in Patients with Advanced Cancer 1 (2006) (0)
A retrospective study of hepatic arterial infusion (HAI) FUDR/Dex and mitomycin C (MMC) for chemotherapy refractory unresectable intrahepatic cholangiocarcinomas (ICC). (2019) (0)
Regional Chemotherapy of Primary and Metastatic Liver Tumors (2007) (0)
Metastases to the Breast from Primary Pancreatic Cancer (2005) (0)
Phase I study of transarterial chemoembolization of lung metastases. (2021) (0)
Factors affecting oncologic outcome after radiofrequency ablation of colorectal liver metastasis (2013) (0)
Clinical outcomes in patients age 40 or younger at diagnosis of synchonous metastatic colorectal cancer. (2011) (0)
Chemotherapy for metastatic colorectal cancer (2010) (0)
Oxaliplatin can be safely infused at a rate of 1mg/m2/min. (2015) (0)
Front & Back Matter (2017) (0)
Oxaliplatin: Mechanism of action and preclinical activity Eric Raymond, Stephen Chaney, Esteban Cvitkovic (2001) (0)
ASO Visual Abstract: Timing of Primary Tumor Resection in Synchronous Metastatic Colon Cancer Patients Undergoing Hepatic Arterial Infusion Pump Placement (2022) (0)
Abstract 392: Delineating genomic heterogeneity in paired primary and metastatic colorectal cancer by massively parallel sequencing. (2013) (0)
Abstract No. 107: Radiofrequency ablation of recurrent colorectal cancer hepatic metastases after hepatectomy (2010) (0)
Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases; results of a safety and feasibility study in the Netherlands (2020) (0)
Surgery for rectal cancer Rudolf Raab, Hans-Joachim Meyer, Uwe Werner (2001) (0)
Incidence and risk factors for biliary sclerosis following adjuvant hepatic arterial infusion with floxuridine after hepatectomy for metastatic colorectal cancer. (2010) (0)
Front & Back Matter (2017) (0)
Abstract No. 141: Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can predict oncologic outcomes: A midterm follow up (2011) (0)
Association of lack of uridine monophophosphate kinase expression in tumor samples from colorectal cancer patients with clinical resistance to 5-Fluorouracil (2004) (0)
Percutaneous radiofrequency ablation of colorectal cancer liver Metastases: Factors Affecting Outcomes—A 10-year Experience at a Single Center 1 (2016) (0)
Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage. (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nancy E. Kemeny?

Nancy E. Kemeny is affiliated with the following schools:

Medical University of Graz
California South Bay University
Thomas Jefferson University

Nancy E. Kemeny's Academic­Influence.com Rankings

Why Is Nancy E. Kemeny Influential?

Nancy E. Kemeny's Published Works

Published Works

What Schools Are Affiliated With Nancy E. Kemeny?

Nancy E. Kemeny's AcademicInfluence.com Rankings